Healthcare / BiotechnologyASX
$0.44
+0.00 (+1.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-659657.00 · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-209.4%
↓Gross Margin
N/A
•Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-3.8M · FCF $-5.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | $719.00 | — | — | $8.0M |
| Net Income | $-3.8M | $-3.8M | $-2.3M | $-3.4M | $-4.3M | — |
| EBITDA | $-3.8M | $-3.8M | $-2.0M | $-3.1M | $-4.2M | — |
| EPS | -0.21 | -0.21 | -0.54 | -1.10 | -1.40 | — |
| Gross Margin | — | — | 100.0% | — | — | 100.0% |
| Operating Margin | — | — | -255131.6% | — | — | — |
| Net Margin | — | — | -313736.4% | — | — | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.26 | 0.26 | 0.17 | -1.07 | 0.94 | — |
| Cash Flow | ||||||
| Free Cash Flow | $-5.3M | $-5.3M | $-155864.00 | $-659657.00 | $-3.6M | — |
| Returns | ||||||
| ROE | -209.4% | -209.4% | -81.2% | 186.1% | -401.0% | — |
| Valuation | ||||||
| P/B | 4.38 | 4.38 | — | — | — | — |
| Growth & Yield | ||||||
| EPS Growth | 61.1% | 61.1% | 50.9% | 21.4% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+79.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.54 → -0.21
Residual
+79.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.